We use cookies on this website. By continuing to use this site without changing your cookie settings, you agree that you are happy to accept our cookies and for us to access these on your device. Find out more about how we use cookies and how to change your cookie settings.

Multiple sclerosis research doubles the number of genetic variants associated with the disease

11 August 2011

Scientists have identified 29 new genetic variants linked to multiple sclerosis, providing key insights into the biology of this debilitating neurological disease. Many of the genes implicated in the study are relevant to the immune system, shedding light onto the immunological pathways that underlie the development of multiple sclerosis.

The research, involving an international team of investigators led by the Universities of Cambridge and Oxford and funded by the Wellcome Trust, is published today in the journal 'Nature'. It is the largest MS genetics study ever undertaken and includes contributions from almost 250 researchers as members of the International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium.

Multiple sclerosis is one of the most common neurological conditions among young adults, affecting around 2.5 million people worldwide. The disease results from damage to nerve fibres and their protective insulation, the myelin sheath, in the brain and spinal cord.

The affected nerves - responsible in health for everyday activities such as seeing, walking, feeling, thinking, and controlling the bowel and bladder - are prevented from 'firing' properly and are eventually destroyed. The findings announced today focus attention on the pivotal role of the immune system in causing the damage and help to explain the nature of the immune attack on the brain and spinal cord.

In this multi-population study, researchers studied the DNA from 9772 people with multiple sclerosis from 15 different countries and compared it to that of 17 376 unrelated healthy controls. They were able to confirm 23 previously known genetic associations and identified a further 29 new genetic variants (and an additional five that are strongly suspected) conferring susceptibility to the disease.

A large number of the genes implicated by these findings have pivotal roles in the workings of the immune system, specifically in the function of T cells (one type of white blood cell responsible for mounting an immune response against foreign substances in the body but also involved in autoimmunity) and the activation of interleukins (chemicals that ensure interactions between different types of immune cells).

One-third of the genes identified in this research have previously been implicated in other autoimmune diseases, such as Crohn's Disease and type 1 diabetes, indicating that - perhaps as expected - the same general processes occur in more than one type of autoimmune disease.

Alastair Compston from the University of Cambridge (who, on behalf of the International Multiple Sclerosis Genetics Consortium, led the study jointly with Peter Donnelly from the Wellcome Trust Centre for Human Genetics, University of Oxford) said: "Identifying the basis for genetic susceptibility to any medical condition provides reliable insights into the disease mechanisms. Our research settles a longstanding debate on what happens first in the complex sequence of events that leads to disability in multiple sclerosis. It is now clear that multiple sclerosis is primarily an immunological disease. This has important implications for future treatment strategies."

Previous research has suggested a link between vitamin D deficiency and an increased risk of multiple sclerosis. Along with the many genes that play a direct part in the immune system, the researchers identified two involved in the metabolism of vitamin D, providing additional insight into a possible link between genetic and environmental risk factors.

Peter Donnelly, who leads the Wellcome Trust Case Control Consortium, added: "Our findings highlight the value of large genetic studies in uncovering key biological mechanisms underlying common human diseases. This would simply not have been possible without a large international network of collaborators and the participation of many thousands of patients suffering from this debilitating disease."

The Wellcome Trust is committed to maximising the health benefits of genetics and genomics. It supports research to understand how genomes function in health and disease and works to ensure that this knowledge generates new health innovations for all.

Dr Michael Dunn, Head of Molecular and Physiological Sciences at the Wellcome Trust, says: "This powerful study provides important clues to help us understand the biology of multiple sclerosis. Unlocking the genetics of MS is the first step towards developing better treatments, but the sheer complexity of the disease highlighted by this study means we must be cautious about how long this will take."

Image: A colour-enhanced image of two myelinated nerve fibres. MS results from damage to nerve fibres and the myelin sheath. Credit: Dr David Furness/Wellcome Images.

Reference

The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 [epub ahead of print]

Share |
> Home > News > 2011
Wellcome Trust, Gibbs Building, 215 Euston Road, London NW1 2BE, UK T:+44 (0)20 7611 8888